Mitchell Reinholt, OD
Optometrist · Warsaw, INNPI 1558700690
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $664 of the $946 with a category attached, or 70.2%. 8 manufacturers reported payments, led by Optos, Inc. at 27.7% of the total. Reporting peaked in 2023 at $258 and has fallen 62.1% since, to $98 in 2025.
Across 39 payments — averaging $24.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optos, Inc.$262
- Johnson & Johnson Vision Care, Inc.$243
- Alcon$234
- Bausch & Lomb Americas Inc.$61
- Bausch & Lomb, A Division Of Bausch Health US, LLC$48
- Coopervision Inc.$43
- plus $54 from 2 others
What the payments were for
- Food & beverage$66470%
- Gifts$394%
- Entertainment$24326%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optos, Inc. | 10 | $262 |
| Johnson & Johnson Vision Care, Inc. | 10 | $243 |
| Alcon | 9 | $234 |
| Bausch & Lomb Americas Inc. | 3 | $61 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $48 |
| Coopervision Inc. | 2 | $43 |
| Carl Zeiss Meditec AG | 2 | $39 |
| LKC Technologies, Inc. | 1 | $15 |
How this compares
$946 in reported general payments places this provider in the 60th percentile of 1,318 optometrist providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 16 | $10,039 |
| LumiganBimatoprost | 13 | $7,772 |
| Travoprost | 11 | $3,095 |
| Latanoprost | 146 | $1,019 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 17 | $761 |
| Timolol Maleate | 28 | $174 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Warsaw
- Ann MaddenWarsaw$24K
- Damon DierkerIndianapolis$707K
- Jason JedlickaBloomington$456K
- Kari RiinaFishers$308K
- Rhonda RobinsonIndianapolis$205K
- John CzajaMerrillville$189K
- Peter KollbaumBloomington$60K
- Ryan GustusBluffton$48K
- Steve VargoHighland$48K
- Helen TzanetakosMunster$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.